dc.contributor.author
Kulbe, Hagen
dc.contributor.author
Otto, Raik
dc.contributor.author
Darb-Esfahani, Silvia
dc.contributor.author
Lammert, Hedwig
dc.contributor.author
Abobaker, Salem
dc.contributor.author
Welsch, Gabriele
dc.contributor.author
Chekerov, Radoslav
dc.contributor.author
Schäfer, Reinhold
dc.contributor.author
Dragun, Duska
dc.contributor.author
Hummel, Michael
dc.contributor.author
Leser, Ulf
dc.contributor.author
Sehouli, Jalid
dc.contributor.author
Braicu, Elena Ioana
dc.date.accessioned
2019-10-29T13:42:04Z
dc.date.available
2019-10-29T13:42:04Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/25834
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-25595
dc.description.abstract
Detection of epithelial ovarian cancer (EOC) poses a critical medical challenge. However, novel biomarkers for diagnosis remain to be discovered. Therefore, innovative approaches are of the utmost importance for patient outcome. Here, we present a concept for blood-based biomarker discovery, investigating both epithelial and specifically stromal compartments, which have been neglected in search for novel candidates. We queried gene expression profiles of EOC including microdissected epithelium and adjacent stroma from benign and malignant tumours. Genes significantly differentially expressed within either the epithelial or the stromal compartments were retrieved. The expression of genes whose products are secreted yet absent in the blood of healthy donors were validated in tissue and blood from patients with pelvic mass by NanoString analysis. Results were confirmed by the comprehensive gene expression database, CSIOVDB (Ovarian cancer database of Cancer Science Institute Singapore). The top 25% of candidate genes were explored for their biomarker potential, and twelve were able to discriminate between benign and malignant tumours on transcript levels (p < 0.05). Among them T-cell differentiation protein myelin and lymphocyte (MAL), aurora kinase A (AURKA), stroma-derived candidates versican (VCAN), and syndecan-3 (SDC), which performed significantly better than the recently reported biomarker fibroblast growth factor 18 (FGF18) to discern malignant from benign conditions. Furthermore, elevated MAL and AURKA expression levels correlated significantly with a poor prognosis. We identified promising novel candidates and found the stroma of EOC to be a suitable compartment for biomarker discovery.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
biomarker discovery
en
dc.subject
differential expression
en
dc.subject
ovarian cancer
en
dc.subject
tumour microenvironment
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.3390/cells8070713
dcterms.bibliographicCitation.journaltitle
Cells
dcterms.bibliographicCitation.number
7
dcterms.bibliographicCitation.originalpublishername
MDPI AG
dcterms.bibliographicCitation.volume
8
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
31336942
dcterms.isPartOf.eissn
2073-4409